In the News
New Money
Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies
Two more pharmas practice their Accent, invest in $75M series C round
Oncology biotech Accent raises $75M to enter the clinic
Pharmas back Accent’s plan to make RNA-targeting cancer drugs
Bristol Myers, J&J fund Lexington cancer biotech’s move into the clinic
Korean Asset Manager Mirae Launches U.S. Biotech Venture Fund
Mirae Asset Capital Life Science Emerges from Stealth with $50M Fund
Investment firm Mirae launches its US biotech VC fund with $50M
New bi-coastal VC firm on the hunt for SpaceX-level biotech deal
Asia-based financial group launches $50M US biotech fund
The XBI comedown after JPM
A South Korean investment firm starts first US biotech fund
WSJ | January 23, 2024
Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies
Yahoo Finance | January 23, 2024
Two more pharmas practice their Accent, invest in $75M series C round
Fierce Biotech | January 23, 2024
Oncology biotech Accent raises $75M to enter the clinic
Endpoints News | January 23, 2024
Pharmas back Accent’s plan to make RNA-targeting cancer drugs
Biopharma Dive | January 23, 2024
Bristol Myers, J&J fund Lexington cancer biotech’s move into the clinic
Boston Business Journal | January 23, 2024
Korean Asset Manager Mirae Launches U.S. Biotech Venture Fund
WSJ | January 18, 2024
Mirae Asset Capital Life Science Emerges from Stealth with $50M Fund
Yahoo Finance | January 18, 2024
Investment firm Mirae launches its US biotech VC fund with $50M
Endpoints News | January 18, 2024
New bi-coastal VC firm on the hunt for SpaceX-level biotech deal
Boston Business Journal | January 18, 2024
Asia-based financial group launches $50M US biotech fund
Fierce Biotech | January 18, 2024
The XBI comedown after JPM
STAT | January 18, 2024
A South Korean investment firm starts first US biotech fund
Biopharma Dive | January 18, 2024